 |
4-[[9-(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol |
|---|---|
| Trade Name | |
| Orphan Indication | Idiopathic pulmonary fibrosis |
| USA Market Approval | USA |
| USA Designation Date | 2011-09-23 00:00:00 |
| Sponsor | Celgene Corporation;33 Technology Drive;Warren, New Jersey, 07059 |
